I Thompson

Summary

Affiliation: University of Texas Health Science Center
Country: USA

Publications

  1. ncbi Association of African-American ethnic background with survival in men with metastatic prostate cancer
    I Thompson
    The University of Texas Health Sciences Center at San Antonio, USA
    J Natl Cancer Inst 93:219-25. 2001
  2. ncbi Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
    J Clin Oncol 25:3076-81. 2007
  3. ncbi Chemoprevention of prostate cancer: lessons learned
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center, San Antonio, TX 78229, USA
    BJU Int 100:15-7. 2007
  4. ncbi Relationship of body mass index and prostate specific antigen in a population-based study
    Ian M Thompson
    Departments of Surgery and Pathology and Cellular and Structural Biology, University of Texas HSC at San Antonio, The San Antonio Center for Biomarkers of Risk of Prostate Cancer SABOR, San Antonio Cancer Institute, TX 78229, USA
    Urol Oncol 22:127-31. 2004
  5. ncbi Prostate-specific antigen in the early detection of prostate cancer
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Tex 78229, USA
    CMAJ 176:1853-8. 2007
  6. ncbi Finasteride decreases the risk of prostatic intraepithelial neoplasia
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center at San Antonio and Southwest Oncology Group, San Antonio, Texas 78229, USA
    J Urol 178:107-9; discussion 110. 2007
  7. ncbi Commentary: the ubiquity of prostate cancer: echoes of the past, implications for the present: "what has been will be again, what has been done will be done again; there is nothing new under the sun." ECCLESIASTES 1:9
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
    Int J Epidemiol 36:287-9. 2007
  8. ncbi Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA
    J Urol 177:1749-52. 2007
  9. ncbi Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center at San Antonio, MC 7845, 7703 Floyd Curl Dr, San Antonio, TX 78229 3900, USA
    JAMA 296:2329-35. 2006
  10. ncbi Recommendations for defining and treating high risk localized prostate cancer
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
    J Urol 176:S6-S10; quiz S3-5. 2006

Research Grants

  1. San Antonio Center - Biomarkers for Prostate Cancer
    Ian Thompson; Fiscal Year: 2007
  2. Improving prostate biopsy efficiency: The finasteride challenge test
    Ian M Thompson; Fiscal Year: 2010

Detail Information

Publications97

  1. ncbi Association of African-American ethnic background with survival in men with metastatic prostate cancer
    I Thompson
    The University of Texas Health Sciences Center at San Antonio, USA
    J Natl Cancer Inst 93:219-25. 2001
    ..To evaluate this question, we examined outcomes of African-American and white men with metastatic prostate cancer in the context of a randomized clinical trial...
  2. ncbi Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
    J Clin Oncol 25:3076-81. 2007
    ..Using data from men in the finasteride group of the Prostate Cancer Prevention Trial (PCPT), we evaluated the impact of prostate-specific antigen (PSA) and other risk factors on the risk of prostate cancer...
  3. ncbi Chemoprevention of prostate cancer: lessons learned
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center, San Antonio, TX 78229, USA
    BJU Int 100:15-7. 2007
  4. ncbi Relationship of body mass index and prostate specific antigen in a population-based study
    Ian M Thompson
    Departments of Surgery and Pathology and Cellular and Structural Biology, University of Texas HSC at San Antonio, The San Antonio Center for Biomarkers of Risk of Prostate Cancer SABOR, San Antonio Cancer Institute, TX 78229, USA
    Urol Oncol 22:127-31. 2004
    ..No relationship was found between BMI and PSA in any ethnic group or in the cohort as a whole. This study suggests that there is no increased risk of overdetection of prostate cancer among obese men due to an elevation in PSA...
  5. ncbi Prostate-specific antigen in the early detection of prostate cancer
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Tex 78229, USA
    CMAJ 176:1853-8. 2007
    ..The terms "normal" and "elevated" as descriptors of PSA results should be abandoned...
  6. ncbi Finasteride decreases the risk of prostatic intraepithelial neoplasia
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center at San Antonio and Southwest Oncology Group, San Antonio, Texas 78229, USA
    J Urol 178:107-9; discussion 110. 2007
    ..In the Prostate Cancer Prevention Trial we evaluated the impact of finasteride on the risk of a needle biopsy diagnosis of high grade prostatic intraepithelial neoplasia...
  7. ncbi Commentary: the ubiquity of prostate cancer: echoes of the past, implications for the present: "what has been will be again, what has been done will be done again; there is nothing new under the sun." ECCLESIASTES 1:9
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
    Int J Epidemiol 36:287-9. 2007
  8. ncbi Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA
    J Urol 177:1749-52. 2007
    ..In the current study we report the impact of finasteride on digital rectal examination sensitivity and specificity...
  9. ncbi Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center at San Antonio, MC 7845, 7703 Floyd Curl Dr, San Antonio, TX 78229 3900, USA
    JAMA 296:2329-35. 2006
    ..However, the optimal management of these patients after radical prostatectomy is unknown...
  10. ncbi Recommendations for defining and treating high risk localized prostate cancer
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
    J Urol 176:S6-S10; quiz S3-5. 2006
  11. ncbi Defining high risk prostate cancer--where do we set the bar? A translational science approach to risk stratification
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
    J Urol 176:S21-4; discussion S25-6. 2006
    ..Risk stratification is commonly used in patients with prostate cancer but this effort has had no demonstrable effect on patient decision making for initial therapy. We propose new risk strata for clinically localized prostate cancer...
  12. ncbi Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center at San Antonio, TX 78229, USA
    JAMA 294:66-70. 2005
    ..Three fourths of US men older than 50 years have been screened with prostate-specific antigen (PSA) for prostate cancer...
  13. ncbi Effect of finasteride on the sensitivity of PSA for detecting prostate cancer
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
    J Natl Cancer Inst 98:1128-33. 2006
    ..We examined the impact of finasteride on the sensitivity and area under the receiver operating characteristic curve (AUC) of prostate-specific antigen (PSA) for detecting prostate cancer...
  14. ncbi Does prostate volume affect accurate grading of prostate biopsies?
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center at San Antonio, TX 78229, USA
    Nat Clin Pract Urol 3:298-9. 2006
  15. ncbi Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center, San Antonio, TX 78229, USA
    J Natl Cancer Inst 98:529-34. 2006
    ..We used prostate biopsy data from men who participated in the Prostate Cancer Prevention Trial (PCPT) to develop a predictive model of prostate cancer...
  16. ncbi Screening for prostate cancer: opportunities and challenges
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center at San Antonio, TX 78229, USA
    Surg Oncol Clin N Am 14:747-60. 2005
    ....
  17. ncbi Phase III prostate cancer prevention trials: are the costs justified?
    Ian M Thompson
    Department of Urology, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78229, USA
    J Clin Oncol 23:8161-4. 2005
    ..Prospective, randomized chemoprevention trials for prostate and other cancers are expensive and require long periods of time to conduct, yet the rewards are on a par with the investment...
  18. ncbi Chemoprevention of prostate cancer: agents and study designs
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA
    J Urol 178:S9-S13. 2007
    ..We review promising agents for prostate cancer prevention, clinical trial designs and how these agents may be used clinically...
  19. ncbi Prostate cancer prevention: what do we know now and when will we know more?
    Ian M Thompson
    Division of Urology, Department of Surgery, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA
    Clin Prostate Cancer 1:215-20. 2003
    ..Many phase II and biomarker-modulation studies are also ongoing, testing a host of other interventions. It is hoped that, within a short period of time, the clinician will be provided with strategies to reduce the risk of the disease...
  20. ncbi Erectile dysfunction and subsequent cardiovascular disease
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
    JAMA 294:2996-3002. 2005
    ..The risk factors for cardiovascular disease and erectile dysfunction are similar...
  21. ncbi Challenges and opportunities to the design and implementation of chemoprevention trials for prostate cancer
    Ian M Thompson
    Division of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
    Urol Oncol 21:73-8. 2003
    ..In this manuscript, we discuss these challenges to the study of prostate cancer prevention and provide a blueprint for prioritization of future studies...
  22. ncbi The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy
    Ian M Thompson
    University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
    J Urol 180:544-7. 2008
    ..We compared the performance operating characteristics of prostate specific antigen for prostate cancer between a first and subsequent prostate biopsy in a group of men with complete verification of cancer status...
  23. ncbi The Prostate Cancer Prevention Trial: design, status, and promise
    Ian M Thompson
    Division of Urology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
    World J Urol 21:28-30. 2003
    ..The high participant interest and extensive data collected for this study demonstrate the extraordinary opportunity for chemoprevention trials of prostate cancer in the United States..
  24. ncbi Chemoprevention of prostate cancer
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA
    J Urol 182:499-507; discussion 508. 2009
    ..We review the most recent results of large scale randomized clinical trials...
  25. ncbi PSA: a biomarker for disease. A biomarker for clinical trials. How useful is it?
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
    J Nutr 136:2704S. 2006
  26. ncbi Prevention of prostate cancer with finasteride: US/European perspective
    Ian M Thompson
    University of Texas Health Science Center, Division of Urology, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
    Eur Urol 44:650-5. 2003
    ..We herein amplify on the results of this trial to assist patients and physicians in reaching individualized decisions...
  27. ncbi First International Conference on Chemoprevention of Prostate Cancer. Overview consensus statement
    Ian M Thompson
    University of Texas Health Science Center at San Antonio, Texas 78229, USA
    J Urol 171:S3-4. 2004
  28. ncbi The Prostate Cancer Prevention Trial: Current status and lessons learned
    I M Thompson
    Division of Urology, University of Texas Health Sciences Center at San Antonio, San Antonio, Texas, USA
    Urology 57:230-4. 2001
    ..With the extraordinary number of potential agents, it is expected that much will be accomplished with this strategy in the near future...
  29. ncbi The Prostate Cancer Prevention Trial and the future of chemoprevention
    Ian M Thompson
    Department of Urology, The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
    BJU Int 101:933-4. 2008
  30. ncbi Does the level of prostate cancer risk affect cancer prevention with finasteride?
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA
    Urology 71:854-7. 2008
    ..8% in the Prostate Cancer Prevention Trial (PCPT). Whether this represents treatment or prevention and who is most likely to benefit are unknown. We sought to clarify these issues by this investigation...
  31. ncbi SELECT: the selenium and vitamin E cancer prevention trial
    Eric A Klein
    Section of Urologic Oncology, Department of Urology, Cleveland Clinic Foundation, Cleveland, OH, USA
    Urol Oncol 21:59-65. 2003
    ..SELECT is a randomized, prospective, double-blind study designed to determine if selenium and vitamin E can reduce the risk of prostate cancer among healthy men...
  32. ncbi Chemoprevention of prostate cancer. Focus on key opportunities and clinical trials
    Robin Leach
    Department of Cellular and Structural Biology, University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
    Urol Clin North Am 30:227-37. 2003
    ..Ultimately, through these efforts, it can be anticipated that the primary focus for control of prostate cancer will shift from early detection and treatment to prevention...
  33. ncbi Management of high-risk localized prostate cancer: the integration of local and systemic therapy approaches
    Samira Syed
    Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Sciences Center, San Antonio, TX, USA
    Urol Oncol 21:235-43. 2003
    ..Patients with high-risk prostate cancer undergoing radiotherapy or surgery should be offered participation in these clinical trials...
  34. ncbi Current age and race adjusted prostate specific antigen threshold values delay diagnosis of high grade prostate cancer
    Amanda Reed
    Department of Urology, University of Texas Health Sciences Center San Antonio, San Antonio, Texas 78229, USA
    J Urol 178:1929-32; discussion 1932. 2007
    ..We suggest that prostate specific antigen is not a dichotomous biomarker and age specific reference ranges delays the diagnosis of high grade prostate cancer in older and black American men...
  35. ncbi Treatment options in lymph node-positive prostate cancer
    Gregory P Swanson
    Department of Radiation Oncology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA
    Cancer 106:2531-9. 2006
    ..There have been a few studies with chemotherapy, and no treatment has been proven superior to the others. Consequently, there remain several reasonable alternatives to treatment, and long-term survival is not unusual...
  36. ncbi Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study
    Anita L Sabichi
    University of Texas M D Anderson Cancer Center, Baylor College of Medicine, Houston, Texas, USA
    Clin Cancer Res 12:2178-84. 2006
    ..Epidemiologic and clinical data suggest that selenium could prevent prostate cancer, but it has not been shown that supplemental selenium leads to an increased concentration of selenium in prostate tissue compared with adjacent tissue...
  37. ncbi Androgens and prevention of prostate cancer
    Jamey A Sarvis
    University of Texas Health Science Center, San Antonio, Texas 78229 3900, USA
    Curr Opin Endocrinol Diabetes Obes 15:271-7. 2008
    ..This review provides a description of recent insights into the role of androgens in prostate cancer prevention...
  38. ncbi Single and multivariate associations of MSR1, ELAC2, and RNASEL with prostate cancer in an ethnic diverse cohort of men
    Joke Beuten
    Department of Pediatrics, University of Texas Health Science Center, San Antonio, TX 78229 3900, USA
    Cancer Epidemiol Biomarkers Prev 19:588-99. 2010
    ..Our findings corroborate the involvement of ELAC2, MSR1, and RNASEL in the etiology of prostate cancer even in individuals without a family history...
  39. ncbi Semaphorin 3B and 3F single nucleotide polymorphisms are associated with prostate cancer risk and poor prognosis
    Joke Beuten
    Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, Texas 78229 3900, USA
    J Urol 182:1614-20. 2009
    ..Each gene has a single nucleotide polymorphism that results in a nonsynonymous coding change, rs2071203 (SEMA3B) and rs1046956 (SEMA3F), as well as noncoding single nucleotide polymorphisms...
  40. ncbi The influence of finasteride on the development of prostate cancer
    Ian M Thompson
    University of Texas Health Science Center, San Antonio, USA
    N Engl J Med 349:215-24. 2003
    ....
  41. ncbi Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter
    Ian M Thompson
    Division of Urology, Department of Surgery, University of Texas Health Science Center at San Antonio, San Antonio, Tex, USA
    N Engl J Med 350:2239-46. 2004
    ..1 to 4.0 ng per milliliter. CONCLUSIONS: Biopsy-detected prostate cancer, including high-grade cancers, is not rare among men with PSA levels of 4.0 ng per milliliter or less--levels generally thought to be in the normal range...
  42. ncbi Serendipitous renal cell carcinoma in the post-CT era: continued evidence in improved outcomes
    Jeffrey A Leslie
    Division of Urology, and the Department of Pathology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
    Urol Oncol 21:39-44. 2003
    ....
  43. ncbi Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial
    Ian M Thompson
    University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
    J Urol 181:956-62. 2009
    ..Extraprostatic disease will be manifest in a third of men after radical prostatectomy. We present the long-term followup of a randomized clinical trial of radiotherapy to reduce the risk of subsequent metastatic disease and death...
  44. ncbi What's new in the field of prostate cancer chemoprevention?
    Kanwaljit Mahal
    Division of Urology, University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
    Curr Urol Rep 6:177-82. 2005
    ..This article examines chemoprevention trials for prostate cancer, including the Prostate Cancer Prevention Trial, Selenium and Vitamin E Cancer Prevention Trial, and cyclooxygenase inhibitors in the prevention of prostate cancer...
  45. ncbi Total prostate specific antigen stability confirmed after long-term storage of serum at -80C
    Amanda Beth Reed
    Department of Urology, University of Texas Health Sciences Center at San Antonio, San Antonio, Texas
    J Urol 180:534-7; discussion 537-8. 2008
    ..We characterized the long-term stability of total prostate specific antigen in serum samples after storage at -80C from 2001 until 2007...
  46. ncbi What's new in the field of prostate cancer chemoprevention?
    Kanwaljit Mahal
    Division of Urology, University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
    Curr Oncol Rep 6:237-42. 2004
    ..This article examines chemoprevention trials for prostate cancer, including the Prostate Cancer Prevention Trial, Selenium and Vitamin E Cancer Prevention Trial, and cyclooxygenase inhibitors in the prevention of prostate cancer...
  47. ncbi Impact of previous local treatment for prostate cancer on subsequent metastatic disease
    Ian M Thompson
    University of Texas Health Science Center at San Antonio, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    J Urol 168:1008-12. 2002
    ..It may provide new opportunities for clinical trials...
  48. ncbi The Prostate Cancer Prevention Trial: current status
    Betsy Higgins
    Divison of Urology, University of Texas Health Science Center at San Antonio, Texas 78229, USA
    J Urol 171:S15-7; discussion S8. 2004
    ..The positive results of the trial as well as many observations that have been made of the study population argue for increased emphasis on prevention research for highly prevalent genitourinary malignancies...
  49. ncbi Association of polymorphisms in TGFB1 and prostate cancer prognosis
    Timothy C Brand
    Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas
    J Urol 179:754-8. 2008
    ..Because of the role of TGFB1 in prostate cancer and progression, we hypothesized that polymorphisms of TGFB1 at C-509T may be associated with prostate cancer risk and/or more aggressive tumors...
  50. ncbi Prostate cancer chemoprevention: update of the prostate cancer prevention trial findings and implications for clinical practice
    Jamey A Sarvis
    Department of Urology, University of Texas Health Science Center San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
    Curr Oncol Rep 10:529-32. 2008
    ..With an excellent safety profile and minimal side effects, men aged 55 years or older should be informed of the opportunity to reduce their risk of prostate cancer with finasteride...
  51. ncbi Association of chromosome 8q variants with prostate cancer risk in Caucasian and Hispanic men
    Joke Beuten
    Department of Pediatrics, University of Texas Health Science Center, San Antonio, TX 78229 3900, USA
    Carcinogenesis 30:1372-9. 2009
    ..This is the first report to investigate the involvement of 8q24 variants in the susceptibility for PCa in Hispanic men...
  52. ncbi Testosterone replacement therapy and prostate cancer: a word of caution
    Timothy C Brand
    Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
    Curr Urol Rep 8:185-9. 2007
    ..A prospective evaluation of prostate cancer risk with testosterone replacement therapy has not been conducted. We outline concerns and recommendations for the use of testosterone replacement therapy in the aging man...
  53. ncbi The potential role of cyclooxygenase-2 inhibitors and 5alpha-reductase inhibitors in the prevention of urologic conditions
    Javier Hernandez
    Division of Urology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
    Urol Clin North Am 31:213-8. 2004
    ..Urologists are frequently providers for and confidants of this patient population and must be able to counsel these men and women about the benefits and risks of such prevention strategies...
  54. ncbi Biomarkers for prostate cancer detection
    Dipen J Parekh
    Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78284 7802, USA
    J Urol 178:2252-9. 2007
    ..New markers that differentiate indolent from aggressive cancers to decrease potential the over treatment of prostate cancer are needed. We reviewed current and potential biomarkers for prostate cancer detection...
  55. ncbi Prostate cancer screening and disease management: how screening may have an unintended effect on survival and mortality-the camel's nose effect
    Rhonda M Walsh
    Department of Urology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA
    J Urol 177:1303-6. 2007
    ..We postulate that a reason for this paradox is increased preventive and therapeutic health care interventions following a prostate cancer diagnosis. We explored this phenomenon in patients surgically treated for prostate cancer...
  56. ncbi Sensitivity and specificity of prostate-specific antigen for prostate cancer detection with high rates of biopsy verification
    Donna Pauler Ankerst
    Dept of Urology, University of Texas Health Science Center at San Antonio, San Antonio, USA
    Arch Ital Urol Androl 78:125-9. 2006
    ..Lowering the PSA threshold for screening increases detection of aggressive cancer at an earlier stage, but has the unavoidable tradeoff of increased detection of the biologically irrelevant cancers...
  57. ncbi Chemoprevention of prostate cancer with finasteride
    Edith D Canby-Hagino
    Department of Urology, University of Texas Health Science Center, San Antonio, TX 78229, USA
    Expert Opin Pharmacother 7:899-905. 2006
    ..Development of a cost-effective chemoprevention strategy for prostate cancer is evolving, and is expected to have significant positive economic and public health benefits...
  58. ncbi Association of RNASEL variants with prostate cancer risk in Hispanic Caucasians and African Americans
    Stacie J Shook
    Department of Cellular and Structural Biology, The University of Texas Health Science Center, San Antonio, Texas 78229 3900, USA
    Clin Cancer Res 13:5959-64. 2007
    ..The RNASEL gene at 1q25 has been identified as a hereditary prostate cancer susceptibility gene, but to date, no study has investigated the role of RNASEL variants in Hispanic Caucasian men with prostate cancer...
  59. ncbi Androgen receptor length polymorphism associated with prostate cancer risk in Hispanic men
    Ivana Balic
    Department of Cellular and Structural Biology, University of Texas Health Science Center San Antonio, San Antonio, Texas, USA
    J Urol 168:2245-8. 2002
    ..A smaller number of repeats is reported to increase the risk of prostate cancer. We investigated the association of CAG repeat length and the risk of prostate cancer in a case-control study of Hispanic men...
  60. ncbi Assessment of 54 biomarkers for biopsy-detectable prostate cancer
    Dipen J Parekh
    Department of Urology, University of Texas Health Sciences Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78284 7802, USA
    Cancer Epidemiol Biomarkers Prev 16:1966-72. 2007
    ....
  61. ncbi Biomarkers for the detection and prognosis of prostate cancer
    Javier Hernandez
    Department of Urology, University of Texas Health Sciences Center, A7703, Floyd Curl Drive, San Antonio, TX 78229, USA
    Curr Urol Rep 6:171-6. 2005
    ..In this review, we highlight some of these ongoing efforts. Proper validation of newly discovered biomarkers is of paramount importance...
  62. ncbi The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group 8794
    Gregory P Swanson
    University of Texas Health Science Center, San Antonio, Texas 78229 3900, USA
    J Urol 180:2453-7; discussion 2458. 2008
    ..From the randomized study Southwest Oncology Group 8794 we evaluated the effect of seminal vesicle involvement on outcomes and whether those patients benefited from post-prostatectomy adjuvant radiation therapy...
  63. ncbi Fast T2*-weighted MRI of the prostate at 3 Tesla
    Rulon L Hardman
    Department of Radiology, University of Texas Health Science Center, San Antonio, TX, USA
    J Magn Reson Imaging 33:902-7. 2011
    ..To compare the sensitivity of T2*W EPI with routinely used T1-weighted turbo-spin echo sequence (T1W TSE) in detecting hemorrhage and the implications on sequences sensitive to field inhomogeneities such as MR spectroscopy (MRS)...
  64. ncbi Prospective evaluation of operating characteristics of prostate cancer detection biomarkers
    Yuanyuan Liang
    Department of Urology, University of Texas Health Science Center, San Antonio, Texas, USA
    J Urol 185:104-10. 2011
    ....
  65. ncbi Prostate cancer: wait or treat? How to apply new findings to your individual situation
    Ian M Thompson
    University of Health Science Center, San Antonio, Texas, USA
    Health News 8:5. 2002
  66. ncbi Body mass index adjusted prostate-specific antigen and its application for prostate cancer screening
    Yuanyuan Liang
    Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
    Urology 76:1268.e1-6. 2010
    ..This study investigated the role of body mass index (BMI) in this assessment...
  67. ncbi Natural products: potential for developing Phellodendron amurense bark extract for prostate cancer management
    Addanki P Kumar
    Department of Urology, School of Medicine, 7703 Floyd Curl Drive, The University of Texas Health Science Center, San Antonio, TX 78229, USA
    Mini Rev Med Chem 10:388-97. 2010
    ..We will discuss the utility of natural products in modulating critical signaling pathways for effective cancer prevention with special emphasis on prostate cancer and their potential translational benefit...
  68. ncbi United States military contributions to the National Cancer Institute
    Jamey A Sarvis
    Department of Urology, University of Texas Health Science Center, San Antonio, TX 78249, USA
    Urol Oncol 27:558-61. 2009
    ..To review contributions from the Department of Defense and the United States military to cancer research and the National Cancer Institute...
  69. ncbi Yearly prostate specific antigen and digital rectal examination fluctuations in a screened population
    Donna Pauler Ankerst
    Depatment of Urology, University of Texas Health Sciences Center, San Antonio, Texas, USA
    J Urol 181:2071-5; discussion 2076. 2009
    ..Prostate biopsy is often recommended based on increases in prostate specific antigen and/or abnormal digital rectal examination. We investigated the stability of a single positive test during the next 3 consecutive years...
  70. ncbi Mechanisms of disease: Prostate cancer--a model for cancer chemoprevention in clinical practice
    Edith D Canby-Hagino
    Department of Urology, University of Texas Health Science Center, San Antonio, TX 78229, USA
    Nat Clin Pract Oncol 2:255-61. 2005
    ..Development of an effective chemoprevention strategy for prostate cancer is evolving and will likely serve as a model for chemoprevention of other adult malignancies...
  71. ncbi Local and systemic therapy for patients with metastatic prostate cancer: should the primary tumor be treated?
    Edith D Canby-Hagino
    Department of Urology, University of Texas Health Sciences Center, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
    Curr Urol Rep 6:183-9. 2005
    ..This evidence is examined and recommendations are made for identifying patients with metastatic prostate cancer who may benefit from definitive treatment of the prostate tumor...
  72. ncbi Obesity, adipokines, and prostate cancer in a prospective population-based study
    Jacques Baillargeon
    Center for Epidemiology and Biostatistics, University of Texas Health Sciences Center at San Antonio, 78284 7802, USA
    Cancer Epidemiol Biomarkers Prev 15:1331-5. 2006
    ..The purpose of this investigation was to examine the association of obesity and the adipokines leptin, adiponectin, and interleukin-6 (IL-6) with prostate cancer risk and aggressiveness...
  73. ncbi Prognostic features in men who died of prostate cancer
    Kadee E Thompson
    Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA
    J Urol 174:553-6; discussion 556. 2005
    ..Treatment decision planning is generally linked to prognostic variables, most notably PSA, clinical stage and Gleason grade. We examined these and other prognostic variables in a cohort of men who ultimately died of prostate cancer...
  74. ncbi Prostate cancer detection strategies
    Timothy C Brand
    Department of Urology, University of Texas Health Science Center, Mail Code 7845, 7703 Floyd Curl Drive, San Antonio, TX 78229 3900, USA
    Curr Urol Rep 7:181-5. 2006
    ..Prevention strategies may be employed for higher-risk patients, and these strategies eventually may be tailored to genetic or other risks...
  75. ncbi External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population
    Dipen J Parekh
    Department of Urology, University of Texas Health Science Center, San Antonio, Texas 78229, USA
    Urology 68:1152-5. 2006
    ....
  76. ncbi Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial
    Ruth D Etzioni
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    J Urol 174:877-81. 2005
    ..We estimated the long-term effects of finasteride on PSA in men with and without a prostate cancer diagnosis at the end of the study...
  77. ncbi Assessing benefit and risk in the prevention of prostate cancer: the prostate cancer prevention trial revisited
    Eric A Klein
    Section of Urologic Oncology, Glickman Urological Institute, Cleveland, OH 44195, USA
    J Clin Oncol 23:7460-6. 2005
    ....
  78. ncbi Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial
    Marian L Neuhouser
    Cancer Prevention Program, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Prostate 68:1477-86. 2008
    ....
  79. ncbi Biomarker-based methods for determining noncompliance in a prevention trial
    Donna K Pauler
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Control Clin Trials 23:675-85. 2002
    ..Our results indicate that simple absolute threshold monitoring rules perform just as well as more complicated rules that utilize the entire biomarker history...
  80. ncbi Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial
    Zhihong Gong
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North M4 B402, Seattle, WA 98109 1024, USA
    Cancer Epidemiol Biomarkers Prev 15:1977-83. 2006
    ..Obesity increases the risk of high-grade but decreases the risk of low-grade prostate cancer, and this relationship is independent of the lower risk for prostate cancer among men with diabetes...
  81. ncbi Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
    Scott M Lippman
    The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Natl Cancer Inst 97:94-102. 2005
    ....
  82. ncbi Clinically localised prostate cancer
    Timothy J Wilt
    Minneapolis VA Center for Chronic Disease Outcomes Research, 1 Veterans Drive (111-0, Minneapolis, MN 55417, USA
    BMJ 333:1102-6. 2006
  83. ncbi It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer
    Ian M Thompson
    J Urol 180:1219-22. 2008
  84. ncbi Prevention of hormone-related cancers: prostate cancer
    Howard L Parnes
    National Cancer Institute, 6130 Executive Blvd, Room 2046, Bethesda, MD 20892, USA
    J Clin Oncol 23:368-77. 2005
    ..best candidates for finasteride chemoprevention, and what are the clinical implications of the high prevalence of prostate cancer that was detected in men with prostate-specific antigen levels in the so-called "normal" range?..
  85. ncbi Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias
    Dale McLerran
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Clin Chem 54:44-52. 2008
    ..Details of this 3-stage process have been described. This report describes the development of the algorithm and results of the blinded test for stage 1...
  86. ncbi Implementation of the Prostate Cancer Prevention Trial (PCPT)
    Phyllis J Goodman
    Southwest Oncology Group Statistical Center, M S M3 C102, 1100 Fairview Avenue North, Box 19024, Seattle, WA 98109 1024, USA
    Control Clin Trials 25:203-22. 2004
    ..We present an overview of the study design, details of the administrative structure of the study and a description of the successful implementation of the accrual phase...
  87. ncbi Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial
    M Scott Lucia
    Department of Pathology, University of Colorado Denver and Health Sciences Center, 4200 E Ninth Ave, Box B 216, Denver, CO 80262, USA
    J Natl Cancer Inst 99:1375-83. 2007
    ..We assessed whether the increased high-grade prostate cancer associated with finasteride in the PCPT was due to finasteride's potential effects on tumor morphology or prostate size...
  88. ncbi The effect of race/ethnicity on the accuracy of the 2001 Partin Tables for predicting pathologic stage of localized prostate cancer
    Elisabeth I Heath
    Barbara Ann Karmanos Cancer Institute, Department of Hematology and Oncology, Wayne State University, 4100 John R, 4 HWCRC, Detroit, MI 48201, USA
    Urology 71:151-5. 2008
    ..To test the accuracy of the 2001 Partin Tables in African American men who underwent radical prostatectomy at multiple centers throughout the United States...
  89. ncbi Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial
    Alan R Kristal
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Am J Epidemiol 167:925-34. 2008
    ..A diet low in fat and red meat and high in protein and vegetables, as well as regular alcohol consumption, may reduce the risk of symptomatic BPH...
  90. ncbi Ten-year survival in patients with metastatic prostate cancer
    Catherine M Tangen
    The Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Clin Prostate Cancer 2:41-5. 2003
    ..Although statistically significant baseline characteristics were identified in this clinical trial, they did not accurately predict the survival interval to which a patient belonged...
  91. ncbi Prostate cancer chemoprevention: an overview of United States trials
    Albaha Barqawi
    Division of Urologic Oncolgy, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    J Urol 171:S5-8; discussion S9. 2004
    ..CONCLUSIONS: Chemoprevention of prostate cancer is currently being tested in a wide range of clinical trials. These studies have the potential to fundamentally alter the current approach to prostate cancer management...
  92. ncbi Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial
    Carol M Moinpour
    Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center M3 C102, 1100 Fairview Ave North, Box 19024, Seattle, WA 98109 1024, USA
    J Natl Cancer Inst 99:1025-35. 2007
    ..The PCPT offered an opportunity to prospectively study the effects of finasteride and other covariates on sexual dysfunction...
  93. ncbi Update on chemoprevention of prostate cancer
    Eric A Klein
    Section of Urologic Oncology, Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Curr Opin Urol 14:143-9. 2004
    ..This overview summarizes the results of that trial, the design of other large-scale trials, and advances in understanding of the molecular mechanisms underlying the effect of other promising agents...
  94. ncbi [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study
    Lori J Sokoll
    Departments of Pathology and Urology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    J Urol 180:539-43; discussion 543. 2008
    ..This study evaluated the [-2]proenzyme prostate specific antigen serum marker using a blinded reference specimen set from 3 National Cancer Institute Early Detection Research Network centers from men with an indication for prostate biopsy...
  95. ncbi Localized prostate cancer: quality of life meets Whitmore's legacy
    Carlos Bermejo
    J Natl Cancer Inst 96:1348-9. 2004
  96. ncbi Integrating the predictiveness of a marker with its performance as a classifier
    Margaret S Pepe
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Am J Epidemiol 167:362-8. 2008
    ..The methods are demonstrated with data on prostate-specific antigen and risk factors from the Prostate Cancer Prevention Trial, 1993-2003...

Research Grants3

  1. San Antonio Center - Biomarkers for Prostate Cancer
    Ian Thompson; Fiscal Year: 2007
    ....
  2. Improving prostate biopsy efficiency: The finasteride challenge test
    Ian M Thompson; Fiscal Year: 2010
    ..We will determine if 3 months of treatment with finasteride will improve prostate cancer detection, with the potential for eliminating many of these unnecessary prostate biopsies. ..